Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-EIR pharmacodynamic study in moderate active Crohn's disease
2011-002821-24Phase 2Terminated
- Sponsor
- Alfa Wassermann
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rifaximin in Crohn's disease, sponsored by Alfa Wassermann. Primary endpoints: Clinical response proportion, Endoscopic improvement proportion and 1 more. Started Feb 2012; status: terminated.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-002821-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002821-24.